Advisors Asset Management, Inc. Chemo Centryx, Inc. Transaction History

Advisors Asset Management, Inc.

$5.28 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 08, 2022	SELL	$22.17 - $51.8 $5,897 - $13,778	-266 Reduced 3.43%	7,486 $387,000
Q2 2022 Aug 08, 2022	SELL	$15.36 - $27.51 $2,042 - $3,658	-133 Reduced 1.69%	7,752 $192,000
Q1 2022 May 17, 2022	SELL	$22.22 - $39.12 $16,153 - $28,440	-727 Reduced 8.44%	7,885 $198,000
Q4 2021 Feb 15, 2022	SELL	$18.38 - $40.5 $5,017 - $11,056	-273 Reduced 3.07%	8,612 $314,000
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $15,855 - $23,855	1,203 Added 15.66%	8,885 $152,000
Q2 2021 Jul 30, 2021	BUY	$9.59 - $50.88 $15,459 - $82,018	1,612 Added 26.56%	7,682 $103,000
Q1 2021 May 07, 2021	BUY	$49.53 - $68.4 $101,586 - $140,288	2,051 Added 51.03%	6,070 $311,000
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $189,897 - $261,878	4,019 New	4,019 $249,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.